Pfizer Inc. (PFE) is a global biopharmaceutical company based in New York. The company makes money by develo꧙ping and manufacturing drug treatments to promote healt🃏h and prevent disease.

I๊ts single operating segment spans a range of therapeutic areas, including oncology, internal medicine, hospitals, vaccines, inflammation and immunology, a♛nd rare diseases.

In FY 2023, Pfizer generated $2.12 billion in net income out of $58.5 billion in annual revenue. The company experienced significant drops in income and revenue due to the decline of COVID-19 products. Revenues in 2022 were $100 billion, down to $58.5 billion in 2023. Net income in 2022 was $31.37 billion, down to $2.12 billion in 2023.

In particular, Comirnaty, the number one revenue generator, was down 70% in 2023. Paxlovid, which was the number two revenue generator, was down 92%, becoming the number seven revenue generator.

The company's market capitalization was approximately $150 billion as of the market close on Jan. 14, 2025.

Understanding Pfizer

In 2023, Pfizer missed its initial projections on business performance, largely due to the decline in sales of its products that treat COVID-19. Its annual revenues of $58.5 billion reflected a 41% decrease from the previous year.

Pfizer's best-selling product by far in 2023 was Comirnaty, its latest-generation Covid vaccine. It alone brought in about $11.2 billion.

Its second most profitable product was Eliquis, an anticoagulant used to treat and prevent blood clots and prevent stroke. This drug, which has ꧟the generic name apixaban, earned about $6.7 billion in 2023.

The Prevnar family of drug immunization therapies to prevent pneumonia, invasive disease, and otitis media caused by Streptococcus pneumonia generated a total of $6.4 billion.

Pfizer's Competitors

Several other large, global drug manufacturers present Pfizer with significant 澳洲幸运5官方开奖结果体彩网:competition.

They include Johnson & Johnson, Roche Holding AG, Eli Lilly and Co., AbbVie Inc., Novo Nordisk, and Merck & Co. Below are some details of these com🦩panies,

澳洲幸运5官方开奖结果体彩网:Market capitalization numbers are as💞 of the close of trading on Jan. 14, 2025. Revenues for Roche Holdin🍨gs and Novo Nordisk were converted from Swiss francs and Danish kroner, respectively, to U.S. dollars.

澳洲幸运5官方开奖结果体彩网:Johnson & Johnson (JNJ)

• Market Cap: $348.50 billion
• FY 2023 Revenue: $85 billion
• FY 2023 Net Income: $35.2 billion
• Top Drug by Revenue (FY 2023): STELARA
• Revenue From Top Drug (FY 2023): $10.9 billion

Johnson & Johnson is known for its many consumer health products, 澳洲幸运5官方开奖结果体彩网:pharmaceuticals, and medical devices. Its sales results for 2023 were $54.8 billion in pharmaceuticals and $30.4 billion in medical devices.

澳洲幸运5官方开奖结果体彩网:Novo Nordisk A/S (NVO)

• Market Cap: $361.93 billion
• FY 2023 Revenue: $33.7 billion
• FY 2023 Net Income: $12.1 billion
• Top Drug by Revenue (FY 2023): Ozempic
• Revenue From Top Drug (FY 2023): $3.9 billion

Novo Nordisk is a Norwegian pharmaceutical manufacturer tha𓄧t focuses on treating diabetes, obesity, and other serious chronic diseases♐ and conditions.

Novo Nordisk's top-selling drug in 2023 was Ozempic, an insulin therapy delivered by injection. Other top sellers for 2023 were Victoza (injection) and Rybelsus, a pill that increases insulin levels in the body to reduce liver sugar production, with combined sales values of $5.8 billion.

澳洲幸运5官方开奖结果体彩网:Eli Lilly and Co. (LLY)

• Market Cap: $707.15 billion
• FY 2023 Revenue: $34.1 billion
• FY 2023 Net Income: $5.2 billion
• Top Drug by Revenue (FY 2023): Trulicity
• Revenue From Top Drug (FY 2023): $7.1 billion

Eli Lilly is a global drug manufacturing company headquartered in Indianapolis. Its business focuses on discovering, developing, manufacturing, and marketing𒁃 human pharmaceutical products. Those products span various therapeutic areas,🦂 including diabetes, oncology, immunology, neuroscience, and more.

Eli Lilly's top-selling drug in FY 2023 was Trulicity, used to treat type 2 diabetes and reduce the risk of significant adverse cardiovascular events. Other top-selling medicines in FY 2023 include:

• Mounjaro, used to treat adults with type 2 diabetes, generated $5.1 billion.
• Breast cancer treatment drug Verzenio generated $3.9 billion.
• Taltz, a treatment for plaque psoriasis, brought in $2.8 billion.

澳洲幸运5官方开奖结果体彩网:AbbVie Inc. (ABBV)

• Market Cap: $310.22 billion
• FY 2023 Revenue: $54.3 billion
• FY 2023 Net Income: $4.9 billion
• Top Drug by Revenue (FY 2023): Humira
• Revenue From Top Drug (FY 2023): $12.2 billion

AbbVie is a global biopharmaceutical company based in Chicago. The company's single business segment is research and development, manufacturing, commercializing, and selling innovative medicines and therapies.

Its products span a range of healthcare-related areas, including immunology, oncology, aesthetics, neuroscience, eye care, women's health, and more.

AbbVie's top-selling drug in FY 2023 was Humira, a biologic therapy used to treat several autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, adult Crohn's disease, and others.

Other top-selling drugs in FY 2023 include immunologic drugs Skyrizi, which brought in $7.8 billion in revenue, and Rinvoq, which generated $4 billion.

澳洲幸运5官方开奖结果体彩网:Merck & Co. Inc. (MRK)

• Market Cap: $252.08 billion
• FY 2023 Revenue: $60.2 billion
• FY 2023 Net Income: $365 million
• Top Drug by Revenue (FY 2023): Keytruda
• Revenue From Top Drug (FY 2023): $25 billion

Merck is a global healthcare company based in Kenilworth, New Jersey. The company produces prescription medicᩚᩚᩚᩚᩚᩚ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ𒀱ᩚᩚᩚines, vaccines, biological therapies, and animal health products. Its two operating segments are pharmaceutical and animal health.

It offers a variety of treatments across a wide range of areas, including oncology, vaccines, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, women's health, livestock products, and companion animal products.

Merck's top-selling drug in FY 2023 was Keytruda, which is used to treat patients with numerous types of cancer including cervical cancer, classical Hodgkin Lymphoma, and certain lung cancers.

Other top-selling drugs in FY 2023 include Human Papillomavirus vaccines Gardasil/Gardasil 9, which generated $8.9 billion in revenue, and Januvia/Janumet, for the treatment of type 2 diabetes, which generated $3.4 billion in revenue. 

澳洲幸运5官方开奖结果体彩网:Roche Holding AG (RHHBY)

• Market Cap: $233.27 billion
• FY 2023 Revenue: $69.1 billion
• FY 2023 Net Income: $14.7 billion
• Top Drug by Revenue (FY 2023): Ocrevus
• Revenue From Top Drug (FY 2023): $7.5 billion

Roche Hಌolding AG is the holding company for F. Hoffman-La Roche AG, the pharmaceutical company known as Roche, a global healthcare company headquartered in Basel, Switzerland. Its business is organized into two main divisions: pharmaceuticals and dia🦋gnostics.

Roche develops drugs and treatments across various areas, including oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolism, ophthalmology, and respiratory ailments.

Roche's top-selling drug in FY 2023 was Ocrevus, used to treat multiple sclerosis. Hemophilia treatment Hemlibra brought in $4.8 billion, and its cancer drug Perjeta generated $4.5 billion.

The Bottom Line

Pfizer began manufacturing chemicals in 1849, eventually pivoting to pharmaceutical research in the 1950s. Since then, it has become one of the biggest pharmaceutical companies in the world, with only a few companies reaching the status of peers.

Pfizer has 30 active pharmaceutical patents. It also has 108 products, as of Oct. 29, 2024, in its development pipeline.